Tag: safety

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Glendale, CA, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Radcred, a trusted U.S. consumer lending brand, RadCred understands that access to emergency funds remains one of the biggest challenges for Americans with poor or limited credit. Federal Reserve data shows that more than 60% of adults cannot cover a $400 unexpected expense without borrowing or selling assets. Traditional banks often reject applicants with low scores, leaving millions to search online for alternatives such as bad credit check loans with guaranteed approval or instant approval no credit check loans.

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

At-home dermaplaning and exfoliation tool for smoother, brighter-looking skin

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On August 14, 2025 the price of Hims & Hers Health (NYSE: HIMS) shares significantly dropped in after-hours trading after the financial press reported that the FTC is probing the company’s advertising practices and whether it makes it too difficult for customers to cancel subscriptions.